UCLA study: creatine supercharges the immune cells that activate cancer-fighters

Key Takeaways

• Creatine was found to supercharge dendritic cells — the specialized immune cells that detect tumors and activate killer T cells to attack them.
• Dendritic cells inside tumors showed elevated creatine transporter gene expression compared to those in healthy tissue, suggesting the cells actively seek creatine in the tumor environment.
• In mouse melanoma models, daily creatine supplementation significantly slowed tumor growth and increased tumor-infiltrating dendritic cell abundance and activation.
• Human dendritic cells treated with creatine showed enhanced activation and improved ability to stimulate T cells against a cancer-associated target.
• Researchers propose creatine could be used as a supplement during immunotherapy and as a tool to improve the potency of dendritic cell-based cancer vaccines.
• This study was conducted in mice and cells, not cancer patients — no clinical recommendations can be drawn yet, and anyone in cancer treatment should consult their physician before supplementing.

What the UCLA study found

Creatine, long used by athletes to improve strength and endurance, may have a meaningful role in cancer immunology. A new study from UCLA, published June 5, 2026 in the journal iScience, found that creatine supercharges dendritic cells — a critical class of immune cells that capture fragments from tumors and train killer T cells to destroy them.

This builds directly on earlier work from the same UCLA lab led by professor Lili Yang, which showed creatine helps killer T cells fight cancer. The new finding adds an important upstream layer: creatine doesn't just fuel the soldiers — it also energizes the commanders who organize the attack.

"What this study shows is that creatine doesn't just help the T cells fighting cancer — it also energizes the entire infrastructure that supports and guides them," said Lili Yang, the study's senior author and a professor of microbiology, immunology and molecular genetics at UCLA. "That makes creatine a promising supplement to holistically support the immune response that modern immunotherapies depend on."

The research was conducted in mouse models and in human cells — not in cancer patients — so it represents a scientifically significant early-stage finding, not a clinical recommendation.

Why dendritic cells are the key to unlocking better immunotherapy

To understand why this finding matters, it helps to understand the role dendritic cells play in anti-cancer immunity.

When a tumor forms, it needs to be detected before it can be destroyed. Dendritic cells act as the immune system's scouts and instructors. They patrol tissues, pick up fragments from cancer cells, and then travel to lymph nodes where they present those fragments to killer T cells — essentially training them to recognize and attack the specific tumor. Without functional dendritic cells, killer T cells may never receive the signal to go to work.

This matters enormously for current immunotherapy. Most approved cancer immunotherapies — including checkpoint inhibitors like PD-1 and PD-L1 blockers — work by targeting killer T cells directly to prevent them from being suppressed. But only about 20 to 40 percent of patients respond to these therapies. One plausible reason is that without adequate dendritic cell function, there is no strong T cell response to unleash in the first place.

If creatine can improve dendritic cell function — energizing the immune system at this earlier, upstream stage — it could potentially help bring the benefits of immunotherapy to more patients who currently don't respond.

What the researchers actually tested — and found

The UCLA team began by examining which metabolic genes were most active in dendritic cells that had infiltrated tumors in mice. They found that the gene encoding the creatine transporter — the protein that pulls creatine inside cells — was markedly elevated in tumor-infiltrating dendritic cells compared to those in healthy tissue. This suggested dendritic cells inside tumors are actively trying to take up more creatine, possibly to meet elevated energy demands in the nutrient-scarce tumor environment.

From there, the researchers ran two sets of experiments:

What happens when you remove creatine access? The team studied dendritic cells engineered to lack the creatine transporter entirely. These cells showed impaired survival, reduced activation, and a weakened ability to prime T cells to mount a tumor response. When creatine-deficient dendritic cells were grown alongside T cells in a lab dish, those T cells divided less and produced fewer of the signaling molecules needed to fight cancer.

What happens when you add more creatine? The researchers then tested the opposite. Giving daily creatine to mouse models of melanoma significantly slowed tumor growth and boosted both the abundance and activation of tumor-infiltrating dendritic cells. Creatine-treated dendritic cells also produced higher levels of chemical signals that draw additional immune cells into the tumor — amplifying the broader anti-tumor response.

Using metabolomics analyses, the researchers found that creatine supplementation raised intracellular ATP levels in dendritic cells. ATP is the energy currency cells use to power virtually every function. Like a battery storing and releasing excess energy on demand, creatine helps dendritic cells maintain stable energy levels even when competing with fast-growing tumor cells for nutrients.

And in human cells? The team also tested creatine on human monocyte-derived dendritic cells, which are often used in dendritic cell cancer vaccines. Creatine treatment enhanced their activation and improved their ability to stimulate human T cells against a cancer-associated target. This is the step that opens the door to potential clinical translation.

Two pathways this research could open: immunotherapy and vaccines

The researchers highlight two complementary ways creatine could potentially be used clinically, based on these findings:

1. As a supplement during active immunotherapy. If creatine supports dendritic cell function in patients who are already receiving immunotherapy, it could potentially enhance the immune response those therapies try to amplify. Many immunotherapy patients currently don't respond because their T cells have never been properly activated in the first place — a problem that starts with dendritic cell insufficiency. Creatine could address that earlier step.

2. As a manufacturing tool for dendritic cell vaccines. Dendritic cell-based cancer vaccines are made by harvesting a patient's own immune cells, loading them with tumor antigens in a lab, and then infusing them back into the patient. The UCLA findings suggest that incorporating creatine during the manufacturing process may boost the potency of these vaccines before they are administered — something that could be tested without requiring patients to take any additional supplements themselves.

"The potential we see here is that creatine could be used in two complementary ways: as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve the quality of dendritic cell-based vaccines before they're administered," said James Elsten-Brown, a co-first author and graduate student in Yang's lab.

"Understanding how to metabolically support dendritic cells is about supporting the entire anti-tumor response, not just the killer T cells at the end of it," added Elliot Kang, a co-first author and former undergraduate researcher in Yang's lab.

The team's next step is to collaborate with physicians on prospective clinical trials testing whether creatine supplementation actually improves outcomes in immunotherapy patients. That work has not yet begun.

What this means for everyday creatine users

For people using creatine for athletic performance, this study is interesting scientific context — but it doesn't change the practical case for supplementation in healthy individuals. Creatine monohydrate has a well-established safety and efficacy record in healthy people at standard doses, and this research adds to an emerging body of evidence that creatine's benefits extend well beyond muscle performance.

What the study does not mean is that creatine prevents cancer, treats cancer, or that people diagnosed with cancer should start taking it based on this research. The study was conducted in mice and cultured human cells, not in cancer patients. There is a significant gap between a compelling mechanistic finding in animals and a proven clinical intervention in humans.

If you are a healthy person using creatine for training, the existing evidence remains strong:

• Creatine monohydrate improves strength, power output, and lean mass in conjunction with resistance training.
• Evidence also supports cognitive benefits in certain populations, including older adults and people under sleep deprivation.
• Standard dosing of 3 to 5 g/day is well-tolerated in healthy individuals without kidney disease.

This new research adds an exciting frontier — immune health — but it is still early-stage science. For product options and what to look for on a creatine label, browse our best creatine in Canada guide or the full product catalog.

Critical caveats: what this study cannot tell us

As with all early-stage research, the most responsible reading requires attention to what this study does not establish:

Mouse models often don't translate to humans. Many promising cancer treatments that work in mouse tumor models have failed in human trials. The immune systems of mice and humans differ in important ways, and tumor microenvironments in animal studies are rarely a perfect mirror of human disease. The fact that this research also included human cell data is encouraging, but those are still lab-dish experiments — not patients.

The dose and form tested are unclear. The UCLA press release describes "daily creatine injections" in the mouse experiments — not oral supplementation. The dose and delivery method in animal studies often differ substantially from what is practical or appropriate in humans. Whether dietary creatine monohydrate at standard supplemental doses would replicate these effects in people is an open question.

This is not a green light for cancer patients. Anyone currently undergoing cancer treatment — including immunotherapy — should not start, stop, or change supplements without consulting their oncologist or treatment team. Some supplements can interact with therapies, and the biology of active treatment is complex. The researchers themselves emphasized this: "anyone undergoing cancer treatment should consult their doctor before adding any supplement to their routine."

No dietary or medical recommendations can be drawn from this study. This is the researchers' own statement in the press release. It is an important one to respect.

The findings are genuinely exciting and scientifically rigorous at the preclinical stage. The path from this kind of discovery to a clinical intervention typically takes years and multiple rounds of human trials. This study is a strong first step, not a finish line.

Key numbers from the UCLA creatine immune study

• 20–40% Current immunotherapy response rate — Most approved checkpoint immunotherapies only work for roughly 20–40% of patients — strengthening dendritic cells could potentially expand that window.
• Dendritic cells The newly identified target — Creatine energizes dendritic cells — the immune system's scouts that detect tumors and activate killer T cells.
• Elevated ATP Creatine's effect inside immune cells — Creatine supplementation raised intracellular ATP levels in dendritic cells, helping them maintain energy in nutrient-scarce tumor environments.
• iScience 2026 Peer-reviewed journal of publication — Published June 5, 2026. Part of ongoing research from Lili Yang's UCLA lab, building on earlier work showing creatine also fuels killer T cells.

Frequently Asked Questions

Sources & Further Reading

• UCLA Health press release: Creatine may supercharge immune cells that are key to fighting cancer (June 5, 2026)
• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine Supplementation — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN